Results 201 to 210 of about 63,205 (262)

Exploring the BICC1 Interactome in HEK293T Cells: Insights Into RNA‐Mediated Protein Networks and Biomolecular Condensates

FASEB BioAdvances, Volume 8, Issue 8, August 2026.
Workflow for BICC1 interactome characterization in HEK293T cells. Cells expressing FLAG‐tagged BICC1 (full‐length or ΔSAM) were subjected to co‐immunoprecipitation under RNA‐preserved (−) or RNase‐treated (+) conditions (1). Interacting proteins were identified by LC–MS/MS (2) and analyzed through protein–protein interaction networks and functional ...
Heloísa Monteiro do Amaral‐Prado, Gabriela Alves Moreira, Cristiane Santos, Fernando Henrique Bosso, Felipe Eduardo Ciamponi, Guilherme Oliveira Barbosa, Mario Henrique Bengtson, Katlin Brauer Massirer   +7 more
wiley   +1 more source

Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol
Rao M, Merrill M, Troxel M, Chiang S, Momeni-Boroujeni A, Hensley ML, Schram AM.   +6 more
europepmc   +1 more source

Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Cheng CC, Ma LJ, Pang XM, Huang TS, Wang MF, Xu JY, Wang RQ, Chen X, Sun K, Zhao WX, Yan M, Wang P.   +11 more
europepmc   +1 more source

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors. [PDF]

JCO Precis Oncol
O'Sullivan Coyne G, Do KT, Kummar S, Piha-Paul S, Rubinstein L, Kinders R, Parchment RE, Wilsker D, Ferry-Galow K, Miller B, Takebe N, Juwara L, Ong MJ, Bruns A, Hogu M, Naqash AR, Mittra A, Voth AR, Doroshow JH, Chen AP.   +19 more
europepmc   +1 more source

Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations. [PDF]

J Cancer Res Clin Oncol
Turaga SM, Hembruff SL, Savelieff MG, Ghosh A, Puri RV, Pathak HB, Paradiso LJ, Myers TJ, Li A, Godwin AK.   +9 more
europepmc   +1 more source

Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review). [PDF]

Oncol Lett
Han Y, Wei L.
europepmc   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, Volume 50, Issue 8, Page 2106-2115, August 2026.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Trapping Poly(ADP-Ribose) Polymerase

The Journal of Pharmacology and Experimental Therapeutics, 2015
Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage. The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.
Yuqiao, Shen, Mika, Aoyagi-Scharber, Bing, Wang   +2 more
openaire   +2 more sources

Poly(ADP-Ribose) Polymerase Inhibitors

Current Medicinal Chemistry, 2003
Poly(ADP-ribose) polymerase-1 (PARP-1) is the principal member of the PARP enzyme family consisting of PARP-1 and several recently identified novel poly(ADP-ribosyl)ating enzymes. PARP-1 functions as a DNA damage sensor and signalling molecule. Upon binding to DNA breaks, activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes ...
Garry J, Southan, Csaba, Szabó
openaire   +2 more sources

Poly ADP-ribose polymerase-1 and health

Experimental Biology and Medicine, 2010
Niacin (vitamin B 3 ) is required to form nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are involved in scores of anabolic and catabolic redox reactions throughout metabolism. It is now understood that NAD +
James B Kirkland
exaly   +3 more sources